Prana Biotechnology Soars; JD.com Hits New High after Recent IPO


Follow this company

Companies Mentioned

NASDAQ:PRAN / NASDAQ:JD
05/28/2014 [ACCESSWIRE]

Prana Biotechnology Limited (NASDAQ: PRAN) shares closed up 21.02% on Tuesday with nearly 5.9 million shares traded. The stock was one of the most active stocks on the NASDAQ and one of the biggest advancers despite no company news released.

Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimer‘s, Parkinson‘s, and Huntington‘s diseases, as well as various cancer and age-related macular degeneration.

Get more information on Prana Biotechnology Limited and free access to the in depth equity report at: www.TrendingWallStreet.com/stockquote/PRAN

TrendingWallStreet.com wants to help everyday people gain awareness about some of the hottest penny stocks trading in the stock market today. TrendingWallStreet.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get full access to our free stock reports.

JD.com, Inc. (NASDAQ: JD) shares hit a new high of $22.98 on Tuesday after the stock’s IPO this last Thursday. “People are buying JD.com largely on wanting exposure to e-commerce and that’s nothing but good for Alibaba,” Max Wolff, chief economist at Citizen.vc, New York-based venture-capital fund. “Excitement about Chinese e-commerce is still strong even if excitement about China has calmed down a bit.”

Beijing Jingdong Century Trading Co., Ltd. operates as an online retailer in China. It retails various categories of products to customers worldwide.

Get more information on JD.com, Inc. and free access to the in depth equity report at” www.TrendingWallStreet.com/stockquote/JD

 

Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

COMMENTS

Leave a comment...
 * 

Your Name
 *